FIELD: biotechnology.
SUBSTANCE: invention relates to an isolated antibody or its antigen-binding fragment that specifically binds to E-selectin, as well as to a composition and a kit containing them. Also an isolated nucleic acid encoding the above antibody is disclosed, as well as a vector and a cell containing it is disclosed. The invention also relates to a method of producing an antibody or its antigen-binding fragment, which involves culturing the above cell.
EFFECT: invention is effective for the treatment of a medical condition, disease or disorder mediated by or associated with E-selectin expression, E-selectin binding to a ligand, or both.
40 cl, 14 dwg, 38 tbl, 34 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES WHICH BIND TO SORTILIN AND INHIBIT THE BINDING OF PROGRANULIN | 2016 |
|
RU2735639C2 |
| CD47-ANTIGEN-BINDING UNIT AND ITS USE | 2018 |
|
RU2780859C2 |
| PROCOAGULANT ANTIBODIES | 2018 |
|
RU2810094C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
| NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
| LIBRARY OF CONCENTRATION-DEPENDENT BINDING MOLECULES | 2012 |
|
RU2732151C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| ANTIGEN-BINDING MOLECULE CAPABLE OF MULTIPLE BINDING TO A VARIETY OF ANTIGEN MOLECULES | 2018 |
|
RU2757786C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| ANTIBODIES BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2015 |
|
RU2730674C2 |
